Soligenix, Inc. (NASDAQ: SNGX) Investor Investigation Over Possible Wrongdoing Announced

Investors who purchased shares of Soligenix, Inc. (NASDAQ: SNGX) have certain options and should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this investigation, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Soligenix
Affected Securities: 
NASDAQ: SNGX

An investigation on behalf of investors in shares of Soligenix, Inc. (NASDAQ: SNGX) was announced over potential breaches of fiduciary duties by certain officers and directors at Soligenix, Inc.

The investigation by a law firm concerns whether certain Soligenix, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.

Princeton, NJ based Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. Soligenix, Inc. reported that its annual Total Revenue declined from over $10.44 million in 2016 to over $5.43 million in 2017 and that its Net Loss increased from over $3.24 million in 2016 to over $7.14 million in 2017.

Shares of Soligenix, Inc. (NASDAQ: SNGX) declined to as low as $0.91 per share in June 2018.